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OBJECTIVES We sought to assess outcomes in a series of young patients with Marfan syndrome and to
define the prevalence of ventricular arrhythmias in this patient population.
BACKGROUND While sudden death is a well-recognized outcome in Marfan syndrome, ventricular arrhyth-
mias are not well described.
METHODS Patients were followed with echocardiography, electrocardiography, and ambulatory electro-
cardiography. The prevalence and associated factors for ventricular dysrhythmias were
defined.
RESULTS Seventy patients with Marfan syndrome diagnosed at birth to 52 years were followed for a
period of up to 24 years. All patients had cardiovascular involvement and were started on
medical therapy. No patient died from aortic dissection, while 4% died from arrhythmias.
Ventricular arrhythmias were present in 21% and were associated with increased left
ventricular size, mitral valve prolapse, and abnormalities of repolarization.
CONCLUSIONS Cardiac complications are rare in young patients with Marfan syndrome receiving medical
therapy and close clinical follow-up. Sudden death still occurs, and appears more common in
patients with a dilated left ventricle. Left ventricular dilation may predispose to alterations of
repolarization and fatal ventricular arrhythmias. (J Am Coll Cardiol 2003;41:329–32)
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Sudden death in Marfan syndrome is commonly due to
aortic dissection (1). Treatment with beta-blockers is
thought to reduce the risk of progressive aortic dilation and
sudden death (2,3). While it has been theorized that the
structural fibrillin defect (4) may affect the myocardium with
a secondary alteration in electrical properties (5), arrhyth-
mias have not been well recognized as a cause of morbidity
and mortality (5). We sought to evaluate a large cohort of
patients with Marfan syndrome followed at a single insti-
tution to assess long-term outcome, with particular empha-
sis on causes of sudden death. In addition, we sought to
define the prevalence of ventricular dysrhythmias and ab-
normalities of repolarization, and to determine clinical
variables associated with ventricular ectopy.
METHODS
Patient population. All consecutive patients with Marfan
syndrome followed in a subspecialty cardiology clinic of a
single institution were identified. The diagnosis of Marfan
syndrome was made in accordance with the revised diag-
nostic criteria (6). Clinical data including age at diagnosis,
duration of follow-up, presence of family history of sudden
death associated with Marfan syndrome, medications, pre-
vious cardiac surgery, and clinical status were obtained.
Echocardiography. All patients underwent semi-annual
echocardiograms. Data obtained from the echocardiogram
at last visit or prior to death was used for data analysis.
Aortic root dimension, obtained from the parasternal long
axis view (7), was expressed as an absolute value, and as a
value normalized for body surface area. Previously reported
normal aortic values were used (8). Aortic root dilation was
defined as being present if the dimension was 2 standard
deviations above predicted. The left ventricular end-
diastolic dimension (LVED) was expressed as an absolute
value, and as a Z-score based on normative data previously
reported (9,10). The presence of mitral valve prolapse
(MVP) and the degree of mitral regurgitation (MR) or
aortic insufficiency were noted.
Electrocardiography. Routine electrocardiogram (ECG)
was performed on initial evaluation of all patients before
starting medical therapy, and repeated yearly. Initial and
most recent ECGs were reviewed, and QTc and QTu
intervals were calculated when a U-wave 50% of the
height of the T-wave was present.
24-h ambulatory ECG monitoring. Patients had an initial
24-h ambulatory ECG monitor placed while off of medi-
cation for assessment of ventricular arrhythmias. All subse-
quent monitoring, in those patients who had multiple
recordings, was while on medication. Ventricular ectopy was
defined as being present if there were 10 premature
From the *University of Arkansas for Medical Sciences, Arkansas Children’s
Hospital, Little Rock, Arkansas; and †The Hospital for Sick Children, University of
Toronto, Toronto, Ontario, Canada.
Manuscript received April 29, 2002; revised manuscript received September 11,
2002, accepted October 10, 2002.
Journal of the American College of Cardiology Vol. 41, No. 2, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. PII S0735-1097(02)02699-2
ventricular contractions per h (11). Ventricular couplets and
runs of ventricular tachycardia were documented.
Data analysis. Data are expressed as frequencies, means 
standard deviations, or medians with ranges where appro-
priate. Patients were divided into two groups based on the
presence or absence of ventricular ectopy. Patient charac-
teristics and test results for the two groups were compared
using Fischer exact test and chi squared analysis for cate-
gorical variables, and t tests and Kruskal Wallis analysis of
variance for continuous variables. Survival from birth, and
from time of diagnosis, for the two groups was plotted using
Kaplan-Meier estimates and compared using the log rank
test. Independent factors associated with the presence of
ventricular ectopy, as specified in the preceding text, were
sought in multiple logistic regression analysis.
RESULTS
Patient population. Seventy patients (34 male and 36
female) with Marfan syndrome were identified, with a
median age at diagnosis of 10 years (range, birth to 52
years). Sixty-three patients (90%) were diagnosed and fol-
lowed from childhood (18 years). Median age at
follow-up was 17 years (range, 1.5 to 55 years) with a
median follow-up duration of 6 years (range, 20.2 months to
24.5 years). A family history of Marfan syndrome was
present in 24 of the 49 families (49%), with a positive family
history of sudden death associated with Marfan syndrome
present in 13 families (27%). All patients were started on
antihypertensive drug therapy for prophylaxis against aortic
root dilation, but only 58 patients (83%) were maintained
on therapy because of the presence of adverse effects.
Twenty-six patients (37%) were maintained on a beta-
blocker, 25 patients (36%) on an angiotensin-converting
enzyme inhibitor, 2 patients (3%) on a calcium-channel
antagonist, and 5 patients (7%) on a combination of the
above agents. The choice of medication was determined by
evolving patient practice.
Six patients (8%) underwent aortic surgery: five requiring
nonemergent aortic root replacement and one requiring
emergency aortic graft placement to repair a ruptured
descending thoracic aortic aneurysm evident on presenta-
tion. No patient required mitral valve surgery.
There were three patient deaths occurring at 11, 21, and
23 years of age. All were sudden, with no evidence of aortic
dissection or other structural causes of death, evident at
autopsy. All deaths were deemed arrhythmogenic.
Cardiac characteristics. Table 1 demonstrates the cardio-
vascular findings. All patients had cardiovascular involve-
ment identified during follow-up, with 63 patients (90%)
having aortic root dilation with a mean aortic dimension of
34  8 mm (129  23% predicted). Left ventricular
dilation, as defined by a Z-score exceeding 2, was present
in 34 patients (68%). Mean percent predicted LVED was
112  15%, with a mean Z-score of 2.2  1.7. Eight
patients (11%) had evidence of reduced left ventricular (LV)
function, with a shortening fraction 30%.
Electrocardiographic characteristics. All patients under-
went ECG at presentation and during routine follow-up.
All patients were found to be in sinus rhythm. Eleven
patients (16%) had QTc prolongation 440 ms on initial
and subsequent ECG. Thirty-seven patients (60%) had
prominent U waves and evidence of a prolonged QTu with
a mean of 622  57 ms.
24-h ambulatory ECG monitoring. Routine 24-h ambu-
latory ECG monitoring has become part of our standard
practice for assessment of patients with Marfan syndrome,
and was performed in 62 patients. Ventricular ectopy (10
premature ventricular contractions/h or ventricular couplets
or ventricular tachycardia) was noted to be present in 13
patients (21%), of whom 4 patients (6%) also had nonsus-
tained ventricular tachycardia. No patient was noted to have
sustained ventricular ectopy (ventricular tachycardia 30 s).
The percent of ventricular ectopic beats ranged from 1% to
24%.
Factors associated with ventricular ectopy. Table 2 sum-
marizes the clinical characteristics. Patients with ventricular
ectopy had a greater prevalence of MVP with associated
MR and LV dilation. These patients had a higher preva-
lence of repolarization abnormalities, with a greater QTc
and QTu interval.
All three deaths occurred in the patients with ventricular
ectopy, with Kaplan-Meier estimates for survival from birth
for both groups shown in Figure 1. When assessing survival
from time of diagnosis, ventricular ectopy remained a
significant predictor (p  0.036).
Abbreviations and Acronyms
ECG  electrocardiogram
LV  left ventricle
LVED  left ventricular end-diastolic dimension
MR  mitral regurgitation
MVP  mitral valve prolapse
Table 1. Cardiac Characteristics
Characteristic Prevalence
Aortic root dilation 63 (90%)
Mitral valve prolapse 34 (49%)
Mitral insufficiency 15 (21%)
Mild 13
Moderate 2
Severe 0
Left ventricular dilation 34 (68%)
Aortic insufficiency 6 (8%)
Mild 4
Moderate 2
Severe 0
Left ventricular systolic dysfunction 8 (11%)
QTc prolongation 11 (16%)
QTu prolongation 37 (60%)
Ventricular ectopy 13/62 (21%)
Ventricular tachycardia 4/62 (6%)
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Multiple logistic regression analysis showed only in-
creased LVED Z-score (odds ratio 2.27 per 1 standard
deviation increase in Z-score; 95% confidence interval, 1.44
to 3.59; p  0.001) to be an independent factor associated
with ventricular ectopy. After controlling for this variable,
the other variables were not independently associated with
the presence of ventricular ectopy, although many of the
variables were highly correlated, particularly with LVED
Z-score. As such, we sought to determine other factors that
were significantly associated with LVED Z-score in the
total study population. Higher LVED Z-score was signif-
icantly associated with a higher percent predicted aortic root
dimension (Pearson correlation r 0.34; p 0.005), longer
corrected QT interval (r  0.50; p  0.001), and longer
corrected QTu interval (r  0.39; p  0.02). A higher
LVED Z-score was noted in patients with a family history
of sudden death (mean 2.85 vs. 1.81 in those without; p 
0.02). Significant independent factors associated with
higher LVED Z-score noted in general linear regression
modeling included longer QTc interval on initial ECG and
the presence of aortic insufficiency.
Four patients had nonsustained ventricular tachycardia on
ambulatory ECG monitoring. Of these patients, two died
suddenly despite medical therapy with beta blockade, one
remains alive on amiodarone with arrhythmia control, and
one patient, desiring no other treatment, remains alive on
beta-blocker therapy alone with persistence of symptomatic
nonsustained ventricular tachycardia.
Table 3 summarizes the clinical features of the nonsur-
vivors. Two patients had stable aortic root dimensions and
the third had undergone previous aortic root replacement.
All nonsurvivors had ventricular couplets or ventricular
tachycardia on routine 24-h ECG assessment.
DISCUSSION
We report on the long-term outcome of a large series of
young patients with Marfan syndrome. Patients were fol-
lowed semi-annually and started on medical management
early in the course of their disease. Over an extended period
of follow-up, few patients required surgical intervention,
however, the incidence of ventricular arrhythmias was sig-
nificant with a mortality rate from presumed arrhythmo-
genic death of 4%, exceeding the rate of aortic rupture.
Left ventricular dilation has been associated with abnor-
malities of repolarization and arrhythmogenic death in
adults with congestive heart failure (12). Even in the
absence of regurgitant lesions, LV dilation occurs com-
monly in patients with Marfan syndrome and is associated
with altered repolarization that may subsequently lead to
ventricular arrhythmias. Patients with Marfan syndrome
have been documented to have increased aortic wall stiffness
(13) that may lead to increased LV afterload and associated
LV dilation. The arrhythmias noted in our patient popula-
tion may have occurred secondary to alterations in repolar-
ization seen in the dilated left heart.
Previous medical therapies have focused on reducing the
progression of aortic root dilation as a means to improving
survival (2,3). Beta-blocker therapy has been routinely used
(2,3). Beta-blockers have been the mainstay of treatment for
repolarization abnormalities seen in other diseases, includ-
ing the long QT syndrome (14), raising the question of
whether patients with Marfan syndrome may receive addi-
tional benefit from such therapy. Angiotensin-converting
Figure 1. Kaplan-Meier estimates of survival from birth stratified by the
presence or absence of ventricular ectopy in patients who had 24-h
ambulatory electrocardiogram assessment.
Table 2. Factors Associated with Ventricular Ectopy
Variable
Ventricular Ectopy
Present
Ventricular Ectopy
Absent p Value
Mean LVED Z score 4.0  1.6 1.6  1.5  0.001
Mean % predicted aortic root size 140  25 127  22 0.06
MVP 13/13 (100%) 21/49 (43%)  0.001
Mitral insufficiency 8/13 (62%) 7/49 (14%)  0.001
Aortic insufficiency 3/13 (23%) 3/49 (6%) 0.1
QTc (ms) 437  33 410  25 0.003
QTu prolongation 652  44 (n  12) 604  62 (n  22) 0.03
Any medical therapy 11/13 (84%) 42/49 (85%) 1
Beta blocker therapy 10/13 (76%) 19/49 (39%) 0.03
Family history of sudden death 8/13 (62%) 15/49 (35%) 0.08
Median age at diagnosis in years (range) 10.2 (3–39) 10 (0–51) 0.69
LVED  left ventricular end diastolic dimension; MVP  mitral valve prolapse.
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enzyme inhibitors have been associated with reduced QT
dispersion, reduced LV size, and improved survival (12) in
adults with congestive heart failure. Their role in Marfan
syndrome remains unknown. Given the association of
angiotensin-converting enzyme inhibitors with reduction in
ventricular size and reduction in MR, one might suspect a
beneficial role of such therapy in this patient group as LV
size and MR were both associated with increased ventricular
ectopy.
Study limitations. Within this study, patients were on a
variety of medical therapies with no discernible benefit of
any one therapy. While we noted a higher prevalence of
ventricular ectopy in patients on beta-blocker therapy, this
may be confounded by the fact that ventricular ectopy was
an indication for such therapy. No inferences regarding the
impact of medical therapies on the incidence of ventricular
arrhythmias can be drawn from this study data alone.
Ventricular ectopy, as defined herein, has previously been
reported to be rare (0% to 6%) amongst healthy controls
(15), but was not reassessed in this study. Ventricular ectopy
is common in adults with isolated MVP (16) and has been
found to be highly correlated with abnormalities of repo-
larization. Mitral valve prolapse may have contributed to the
increased frequency of ventricular arrhythmias noted in our
study population. As the number of patient deaths in this
study were few, it is difficult to fully gauge the clinical
impact of ventricular arrhyhmias in Marfan patients. On-
going study of the causes of sudden death in Marfan
patients is required. We chose to assess impact of ventricular
ectopy on survival from the time of birth rather than from
the time of diagnosis as Marfan syndrome is a congenital
condition. It is possible that some patients died without a
diagnosis of Marfan syndrome being made which would
alter the survival curve.
CONCLUSIONS
In summary, we have documented a high prevalence of LV
dilation with associated abnormalities of repolarization in a
large series of children and adults with Marfan syndrome.
Such repolarization abnormalities are associated with an
increased risk of ventricular ectopy and possibly sudden
death. Routine 24-h ECG monitoring is critical to the
ongoing assessment of these patients. Close follow-up of
patients, even in the presence of a stable aortic root
dimension, is required. Patients with Marfan syndrome and
ventricular dysrhythmias may be at particularly high risk for
sudden death. Aggressive treatment modalities including
amiodarone or internal defibrillators may be warranted in
select patients. Further research into the effects of routinely
employed anti-hypertensives on ventricular performance,
repolarization and the incidence of ventricular ectopy, in
this patient group is suggested.
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Table 3. Characteristics of Nonsurvivors
Fam Hx
SD
Age at Dx
(yrs) Meds
Age at
Death %SF
LVED
Z score
LVED
(mm) MVP MR AI
% Predicted
Aortic Root
QTc
(ms)
 10 BB 23 35 5.5 59  moderate  158% 517
 10 BB 11 33 5.1 63  None  130% 426
 7 BB 21 25 3.7 58  Mild  176% 450
AI aortic insufficiency; BB beta blocker; Dx diagnosis; Fam Hx SD family history of sudden death; LVED left ventricular end diastolic dimension at time of Holter;
Meds  medications; MR  mitral insufficiency; MVP  mitral valve prolapse; %SF  percent shortening fraction
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